Focal Therapy for Oligometastatic and Oligoprogressive Renal Cell Carcinoma: a Narrative Review

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Sep 11

PMID 39258792

Authors

August C Anderson

Joel Ho

Evan T Hall

Raquibul Hannan

Jay J Liao

Alexander V Louie

Ting Martin Ma

Sarah P Psutka

Ramesh Rengan

Shankar Siva

Anand Swaminath

Lisa Tachiki

Chad Tang

Bin Sing Teh

Joseph Tsai

Scott S Tykodi

Emily Weg

Nicholas G Zaorsky

Simon S Lo

Affiliations

Soon will be listed here.

Abstract

Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.

References

Meyer C, Sun M, Karam J, Leow J, de Velasco G, Pal S . Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. Eur Urol. 2017; 72(2):171-174. DOI: 10.1016/j.eururo.2017.03.005. View

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Venturini M, Cariati M, Marra P, Masala S, Pereira P, Carrafiello G . CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours. Cardiovasc Intervent Radiol. 2020; 43(5):667-683. DOI: 10.1007/s00270-020-02432-6. View

Mikhail M, Chua K, Khizir L, Tabakin A, Singer E . Role of metastasectomy in the management of renal cell carcinoma. Front Surg. 2022; 9:943604. PMC: 9372304. DOI: 10.3389/fsurg.2022.943604. View

Grunwald V, Eberhardt B, Bex A, Florcken A, Gauler T, Derlin T . An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol. 2018; 15(8):511-521. PMC: 7136176. DOI: 10.1038/s41585-018-0034-9. View

Joyce D, Psutka S, Groeschl R, Thompson R, Boorjian S, Cheville J . Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. Urology. 2016; 99:155-161. DOI: 10.1016/j.urology.2016.08.015. View

Iyengar P, Wardak Z, Gerber D, Tumati V, Ahn C, Hughes R . Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2017; 4(1):e173501. PMC: 5833648. DOI: 10.1001/jamaoncol.2017.3501. View

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View

Meyer C, Groeben C, Marks P, Koch R, Huber J . Trends of Metastasis-Directed Treatments in Patients with Renal Cell Carcinoma: A Total Population-Based Analysis in Germany in the Era of Targeted Therapies. Oncol Res Treat. 2020; 43(12):679-685. DOI: 10.1159/000511753. View

10.

Campbell S, Uzzo R, Karam J, Chang S, Clark P, Souter L . Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J Urol. 2021; 206(2):209-218. DOI: 10.1097/JU.0000000000001912. View

11.

Flanigan R, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford E . Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171(3):1071-6. DOI: 10.1097/01.ju.0000110610.61545.ae. View

12.

Tang C, Msaouel P, Hara K, Choi H, Le V, Shah A . Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021; 22(12):1732-1739. DOI: 10.1016/S1470-2045(21)00528-3. View

13.

Genshaft S, Suh R, Abtin F, Baerlocher M, Chang A, Dariushnia S . Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs: Endorsed by the Canadian Association for Interventional Radiology, the.... J Vasc Interv Radiol. 2021; 32(8):1241.e1-1241.e12. DOI: 10.1016/j.jvir.2021.04.024. View

14.

McIntosh A, Umbreit E, Holland L, Gu C, Tannir N, Matin S . Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020; 126(17):3950-3960. DOI: 10.1002/cncr.32991. View

15.

Hasanov E, Yeboa D, Tucker M, Swanson T, Beckham T, Rini B . An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin. 2022; 72(5):454-489. DOI: 10.3322/caac.21729. View

16.

Sohaib S, Cook G, Allen S, Hughes M, Eisen T, Gore M . Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol. 2009; 82(980):632-9. DOI: 10.1259/bjr/52773262. View

17.

Lyon T, Roussel E, Sharma V, Carames G, Lohse C, Costello B . International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma. Eur Urol Oncol. 2022; 6(1):76-83. DOI: 10.1016/j.euo.2022.11.003. View

18.

Mejean A, Ravaud A, Thezenas S, Colas S, Beauval J, Bensalah K . Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5):417-427. DOI: 10.1056/NEJMoa1803675. View

19.

Muselaers S, Erdem S, Bertolo R, Ingels A, Kara O, Pavan N . PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. J Clin Med. 2022; 11(7). PMC: 8999609. DOI: 10.3390/jcm11071829. View

20.

Zaorsky N, Wang X, Garrett S, Lehrer E, Lin C, DeGraff D . Pan-cancer analysis of prognostic metastatic phenotypes. Int J Cancer. 2021; 150(1):132-141. PMC: 8595638. DOI: 10.1002/ijc.33744. View